Skip to main content
ORIGINAL REPORTS
May 01, 2002

Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults With Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study

Publication: Journal of Clinical Oncology

Abstract

PURPOSE: To compare survival and toxicity in adult patients treated with low-dose (50.4 Gy/28 fractions) versus high-dose (64.8 Gy/36 fractions) localized radiation therapy (RT) for supratentorial low-grade astrocytoma, oligodendroglioma, and mixed oligoastrocytoma.
PATIENTS AND METHODS: From 1986 to 1994, 203 eligible/analyzable patients were randomized: 101 to low-dose RT, 102 to high-dose RT. Almost half were younger than 40 years, and 95% had grade 2 tumors. Histologic subtype was astrocytoma (or mixed oligo-astrocytoma with astrocytoma dominant) in 32% of patients and oligodendroglioma (or oligoastrocytoma with oligodendroglioma dominant) in 68%. Tumor diameter was less than 5 cm in 35% of patients, and 41% of tumors showed some degree of contrast enhancement. Extent of resection was gross total in 14% of patients, subtotal in 35%, and biopsy only in 51%.
RESULTS: At the time of the present analysis, 83 patients (41%) are dead, and median follow-up is 6.43 years in the 120 who are still alive. Survival at 2 and 5 years is nonsignificantly better with low-dose RT; survival at 2 and 5 years was 94% and 72%, respectively, with low-dose RT and 85% and 64%, respectively, with high-dose RT (log rank P = .48). Multivariate analysis identified histologic subtype, tumor size, and age as the most significant prognostic factors. Survival is significantly better in patients who are younger than 40 years and in patients who have oligodendroglioma or oligo-dominant histology. Grade 3 to 5 radiation neurotoxicity (necrosis) was observed in seven patients, with one fatality in each treatment arm. The 2-year actuarial incidence of grade 3 to 5 radiation necrosis was 2.5% with low-dose RT and 5% with high-dose RT.
CONCLUSION: This phase III prospective randomized trial of low- versus high-dose radiation therapy for adults with supratentorial low-grade astrocytoma, oligodendroglioma, and oligoastrocytoma found somewhat lower survival and slightly higher incidence of radiation necrosis in the high-dose RT arm. The most important prognostic factors for survival are histologic subtype, tumor size, and age. The study design of the ongoing intergroup trial in this population will be discussed.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Journal of Clinical Oncology
Pages: 2267 - 2276
PubMed: 11980997

History

Published in print: May 01, 2002
Published online: September 21, 2016

Permissions

Request permissions for this article.

Authors

Affiliations

E. Shaw
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
R. Arusell
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
B. Scheithauer
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
J. O’Fallon
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
B. O’Neill
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
R. Dinapoli
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
D. Nelson
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
J. Earle
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
C. Jones
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
T. Cascino
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
D. Nichols
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
R. Ivnik
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
R. Hellman
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
W. Curran
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.
R. Abrams
From the North Central Cancer Treatment Group Operations Office, Rochester, MN; Eastern Cooperative Oncology Group Operations Office, Brookline, MD; and Radiation Therapy Oncology Group Operations Office, Philadelphia, PA.

Notes

Address reprint requests to E. Shaw, MD, Department of Radiation Oncology, Wake Forest University (WFU) School of Medicine at the WFU Baptist Medical Center, Medical Center Blvd, Winston-Salem, NC 27157-1030; email: [email protected].

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
E. Shaw, R. Arusell, B. Scheithauer, J. O’Fallon, B. O’Neill, R. Dinapoli, D. Nelson, J. Earle, C. Jones, T. Cascino, D. Nichols, R. Ivnik, R. Hellman, W. Curran, R. Abrams
Journal of Clinical Oncology 2002 20:9, 2267-2276

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

Purchase this article to get full access to it.

Purchase this Article

Subscribe

Subscribe to this Journal
Renew Your Subscription
Become a Member

View options

View Full Text HTML

View Full Text HTML

PDF

View PDF

Media

Figures

Other

Tables

Share

Share

Share article link

Share